Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Singapore-based S*BIO inked a development collaboration and option and license agreement with Onyx Pharmaceuticals for S*BIO's two JAK2 inhibitors SB1518 and SB1578, S*BIO announced Jan. 6

You may also be interested in...



CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line

The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.

Singapore’s S*BIO Finds Ideal Partner In CTI For Its JAK2 Inhibitor Abandoned By Onyx

Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.

CTI Sees Ideal Pipeline Acquisition In JAK2 Inhibitor Abandoned By Onyx

Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.

Related Content

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel